NEW YORK – Bristol Myers Squibb said on Monday that the European Medicines Agency has accepted its marketing authorization application for nivolumab (Opdivo) with chemotherapy as a first-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.